Comparison of MMSE (Mini-Mental State Examination) and MoCA (Montreal Cognitive Assessment) in Cognitive Assessment in Geriatric Oncology (MoCA)

March 31, 2017 updated by: Centre Francois Baclesse
Compare neurocognitive testing MMSE (Mini-Mental State Examination) and MoCA (Montreal Cognitive Assessment) to candidates aged patients with 1st line treatment of their cancer will be received an examination oncogériatric

Study Overview

Study Type

Observational

Enrollment (Actual)

66

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Caen, France
        • Centre Francois Baclesse
      • Caen, France, 14033
        • CHU

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

71 years and older (Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

aged patients with 1st line treatment of their cancer will be received an examination oncogériatric

Description

Inclusion Criteria:

  • Patient old over 70 years
  • Patient with cancer (solid tumor or hematological) for which a 1st line treatment is planned
  • Patient candidate an oncogeriatric assessment
  • Patient agreeing to participate in the study
  • French language
  • Lack of subsequent neurological sequelae with cognitive impact stroke, dementia or progressive psychiatric disorder
  • Patient having a life expectancy ≥ 6 months

Exclusion Criteria:

  • Primitive cancer of the central nervous system or brain metastasis
  • Patients unable to meet the cognitive tests
  • Refusal to participate
  • Realization of a MMSE or MoCA test in the last 6 months

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
proportion of patients with cognitive disorders identified by the MoCA or the MMSE prior to treatment
Time Frame: before their first treatment for the cancer, at inclusion
before their first treatment for the cancer, at inclusion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Heidi LAVIEC, MD, Centre François Baclesse - CAEN

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2015

Primary Completion (Actual)

March 1, 2017

Study Completion (Actual)

March 1, 2017

Study Registration Dates

First Submitted

September 18, 2015

First Submitted That Met QC Criteria

September 23, 2015

First Posted (Estimate)

September 24, 2015

Study Record Updates

Last Update Posted (Actual)

April 4, 2017

Last Update Submitted That Met QC Criteria

March 31, 2017

Last Verified

June 1, 2016

More Information

Terms related to this study

Other Study ID Numbers

  • MOCA

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cancer

Clinical Trials on cognitive evaluation by MMS (Mini-Mental State Examination) and MoCA (Montreal Cognitive Assessment) tests

Subscribe